Pfenex Gives Teriparatide Latest After Setback

As Company Underlines Confidence In Supply Chain

Pfenex has provided an update on its bid to secure a therapeutic equivalence determination for its PF708 teriparatide product in the US, after itself and partner Alvogen were knocked back last month.

FDA_Truck
The FDA has told Pfenex that further information is required for teriparatide • Source: Shutterstock

Pfenex’ manufacturing and marketing partner for follow-on Forteo (teriparatide), Alvogen, has “begun discussing next steps” with the US Food and Drug Administration after the agency last month served the firms with a notice to conduct further studies to prove that their PF708 teriparatide product is therapeutically equivalent to Eli Lilly’s reference product.

The FDA approved Pfenex’ hybrid 505(b)(2) new drug application for PF708, to be known as Bonsity, in October last year,...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Strategy

More from Business